early peek at data on remdesivir suggests patients are unable to treatment
early peek at data on remdesivir suggests patients are unable to treatment
all the patients have been treated with daily infusions of remdesivir.", "early peek at data on gilead coronavirus drug suggests patients are responding to treatment a vial of the remdesivir, an investigational drug from gilead.", "provided gilead has not restricted access to their drug for these trials and they have managed to recruit and follow up sufficient patients, we have the hope of finding whether remdesivir does have genuine efficacy and safety based on good evidence.")